Related Experiment Video
Updated: Nov 22, 2025

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Combinatorial Strategies for Long-term Control of HIV Infection
Daekee Kwon1, Mi-Jung Han1, Kwang-Won Seo1
1Stem Cells and Regenerative Bioengineering Institute in Kangstem Biotech, Gwangmyeong SK TechnoPark, Gyeonggi-do, Seoul, South Korea.
Insights
Patient-specific CCR5 gene-edited hematopoietic stem cells (HSC) offer a promising approach for long-term HIV control. Combining gene editing with cellular reprogramming overcomes challenges in matching HSC for transplantation.
Area of Science:
- * Hematology
- * Immunology
- * Gene Therapy
Background:
- * Acquired Immunodeficiency Syndrome (AIDS) results from chronic Human Immunodeficiency Virus (HIV) infection.
- * Bone marrow transplantation of hematopoietic stem cells (HSC) with innate C-C chemokine receptor type 5 (CCR5) mutations shows potential for long-term HIV control.
- * A significant hurdle is the difficulty in obtaining CCR5-mutant HSC that are human leukocyte antigen (HLA)-matched between donor and recipient.
Purpose of the Study:
- * To review and discuss methods for generating patient-specific CCR5 gene-edited HSC.
- * To explore the integration of gene editing and cellular reprogramming technologies for HIV therapeutic applications.
Main Methods:
- * Utilizes advanced gene editing tools: zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR).
- * Integrates cellular reprogramming technologies: somatic cell nuclear transfer (SCNT), induced pluripotent stem cells (iPSC), and direct phenotypic conversion.
- * Focuses on generating patient-specific CCR5-edited HSC to overcome HLA matching limitations.
Main Results:
- * The combination of gene editing and cellular reprogramming enables the creation of patient-specific CCR5-edited HSC.
- * These engineered HSC hold potential for addressing the HLA matching challenge in transplantation.
Conclusions:
- * Patient-specific CCR5 gene-edited HSC represent a viable strategy for future HIV therapies.
- * These cellular agents could provide a pathway for long-term control of HIV infection in patients.
Abstract:
AIDS is a disease caused by a chronic infection of HIV. Recently, long-term control of HIV infection has been demonstrated through the bone marrow transplantation of hematopoietic stem cells (HSC), in which the C-C chemokine receptor type 5 (CCR5) gene is mutated innately. However, it is very difficult to obtain CCR5 mutant HSC that match human leukocyte antigen between donor and recipient. To solve this problem, this review will summarize and discuss various reports related to the generation of patient-specific CCR5 geneedited HSC. The fusion of current gene editing (zinc-finger nuclease, transcription activator-like effector nuclease, and clustered regulatory interspaced short palindromic repeats) and cellular reprogramming technology (somatic cell nuclear transfer, induced pluripotent stem cells technology, and direct phenotypic conversion) enables the generation of patient-specific CCR5 edited HSC. These cells can be useful as valuable therapeutic agents for long-term control of HIV-infected patients in the future.
Related Concept Videos
Retrovirus Life Cycles
Size and Structure of Viral Genomes
Viruses with RNA Genomes

